Mission Therapeutics Appoints Dr Anne Phelan as Senior Vice President, Head of Discovery Research

CAMBRIDGE, UK – 20 March 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017.

Dr Phelan has spent over 20 years in the pharmaceutical industry and brings with her a wealth of drug discovery experience across a number of therapy areas as well as operational knowledge. She joins Mission from BenevolentAI (formerly Stratified Medical), where she served as VP, Drug Discovery. Previously, she held a number of senior positions within Pfizer including COO and Head of Pharmacology at Pfizer Neusentis in Cambridge UK.

Dr Phelan obtained her undergraduate and doctoral degrees in Genetics from the University of Liverpool, and carried out her post-doctoral training at the MRC Institute of Virology in Glasgow.

Commenting on the appointment, Dr Anker Lundemose, Chief Executive Officer, said:

“Anne’s appointment further reinforces our scientific expertise and operational capabilities as we consolidate our DUB discovery platform and focus on identifying novel disease targets and producing next generation compounds. She will play an invaluable role as we continue to build our internal pipeline and prioritise novel therapeutic programmes for pre-clinical and clinical development. We are pleased to welcome Anne to our leadership team.”

Dr Anne Phelan newly appointed SVP, Head of Discovery Research, added: “Mission has rapidly earned a reputation as a leading biotech in the Cambridge, UK area. The Company’s science and unique DUB platform, with applicability across numerous therapeutic areas, is impressive and has significant commercial potential. I am looking forward to working alongside Mission’s highly experienced and ambitious leadership team to advance its programmes beyond the discovery phase.”

 

For more information:

CONTACT:

 Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2029 / +44 (0) 20 7457 2061

missiontherapeutics@instinctif.com

 Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

  

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics, an early-stage drug development company targeting the ubiquitin pathway for the treatment of cancer, neurodegenerative, and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Cancer Research UK Laboratories and the University of Cambridge’s Jackson Laboratories at the Gurdon Institute, and a leadership team that has broad international, commercial and scientific experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One.

Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

 

Mission Therapeutics Appoints Colin Goddard as Chairman

Michael Moore Transitions to Deputy Chairman

CAMBRIDGE, UK – 5 December 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announces that Dr Colin Goddard has been appointed as non-executive Chairman, effective January 1st 2017. Dr Colin Goddard joined the board of Mission Therapeutics as a non-executive Director in July 2015. Michael Moore, Mission’s Founder Chairman, will continue on the board and transition to the role of Deputy Chairman.

Dr Michael Moore, Mission Therapeutics retiring Chairman, said: “On behalf of the Board, it gives me great pleasure to welcome Colin in his new role as the Company progresses to the next phase of its evolution. I look forward to continuing to work with him and the Board of Directors as, together with an outstanding management team we continue to shape the Company’s strategy. Colin’s timely accession extents the business reach of Mission commensurate with the significant advances in R&D.”

Dr Colin Goddard, newly appointed Chairman of Mission Therapeutics, added: “I would like to thank Michael for his guidance and support since joining the Board and I look forward to working with the Executive team and my Board colleagues as we build on Mission’s achievements to date. I firmly believe that the Company’s innovative DUB platform can yield transformational, first in class new therapies that address a broad range of unmet clinical needs.”

Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We would like to thank Michael for his robust support and broad expertise during the formative period of the Company and for his role in nurturing the establishment of a powerful drug discovery platform and emerging product pipeline. Colin has a long track record of leadership and success in the industry including as Executive Chairman and CEO of both public and private US biopharma companies and we look forward to leveraging his experience as we exploit our pipeline and transition into a clinical stage company.”

Prior to joining Mission Therapeutics, Dr Goddard was Chief Executive Officer of OSI Pharmaceuticals. He joined the company as a research scientist in 1989 and led the transformation from a technology platform services company into a profitable fully integrated biopharmaceutical organisation, becoming CEO in 1998. He was pivotal in the registration and launch of OSI’s targeted therapeutic product, Tarceva (erlotinib) and also directed the Company’s financing, corporate development and acquisition strategies, completing several major acquisitions and divestitures and raising over $1.5bn in capital. OSI was acquired by Astellas Pharma Inc. in June 2010 for $4bn.

Dr Goddard obtained his PhD in cancer pharmacology from the University of Aston in Birmingham, UK and worked at the National Cancer Institute, Bethesda, MD, before joining OSI. He currently serves as Chairman & CEO of US based Biotech company, BlinkBio, Inc and as a Director on the boards of Endocyte Inc (NASDAQ: ECYT). He was formerly a Director at Human Genome Sciences Inc.

 

ENDS

For more information:

CONTACT:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 1223 497199

 

Hume Brophy

Conor Griffin, Alexia Faure, Alex Protsenko

Email: Missiontherapeutics@humebrophy.com

Tel: +44 20 7862 6381

 

Westwicke Partners (U.S.)

Chris Brinzey

Chris.brinzey@westwicke.com

339-970-2843

 

NOTES TO EDITORS:

 

About Mission Therapeutics

Mission Therapeutics, an early-stage drug development company targeting the ubiquitin pathway for the treatment of cancer, neurodegenerative, and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. Mission has strong links with key academic and research centers, including Cancer Research UK Laboratories and the University of Cambridge’s Jackson Laboratories at the Gurdon Institute, and a leadership team that has broad international, commercial and scientific experience. In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

 

 

Mission Therapeutics to Attend and Present at Conferences in October and November 2016

CAMBRIDGE, UK – 13 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:

(1) ELRIG Drug Discovery 2016

13-14 October 2016, ACC, Liverpool, UK

The Drug Discovery meeting will feature over 50 world-class speakers in six main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. This conference will explore innovative technologies and approaches that can be used to overcome drug development challenges, and bring together industry leaders who will discuss future opportunities for novel therapeutic discovery.

(2) The Lancet Neurology Conference

19-21 October 2016, Park Plaza Riverbank, London, UK

The Lancet Neurology Conference aims to disseminate cutting-edge findings on preclinical neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The event will provide a unique platform for specialists to come together across disciplines for an authoritative discussion of the methodological, regulatory, and ethical considerations of research in people at asymptomatic states of neurodegenerative disease.

(3) The Parkinson’s Disease Therapeutics Conference

24 October 2016, Convene Midtown East, New York, USA

Michael Koslowski, CMO, to attend the event

The Parkinson’s Disease Therapeutics Conference is The Michael J. Fox Foundation’s annual scientific conference focused exclusively on Parkinson’s disease drug development. The event brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

(4) SR One Leaders Retreat

25 October 2016, Miami, Florida, US

Anker Lundemose, CEO, to attend the event

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies.

(5) BIO-Europe

7-9 November 2016, Cologne, Germany

Paul Wallace, CBO, to attend the conference

BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference attracts leading dealmakers from biotech, pharma and finance along with exciting emerging companies. BIO-Europe is regarded as a “must attend” event for the biotech industry.

(6) Jefferies Global Healthcare Conference

16-17 November 2016, The Waldorf Hilton Hotel, London, UK

Anker Lundemose, CEO, and David Luther, CFO, to attend the event

The two-day event will include company presentations, thematic panel discussions, 1×1 investor meetings and, as a continuing unique feature, business-to-business meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

(7) Biotech and Money Inv€$tival Showcase

18 November 2016, The Waldorf Hilton Hotel, London, UK

Anker Lundemose, CEO, to present at the event

Biotech and Money are hosting the Biotech and Money Inv€$tival Showcase, in exclusive partnership with Jefferies LLC. The event showcases the latest investable public and private life science opportunities. Companies ranging from the latest start-ups through to growing public companies, will present to an audience of global investors and pharma. The conference enables investors to uncover and identify investable opportunities with 1-2-1 partnering throughout the day.

For further events, please visit the MISSION Therapeutics website

For more information:

CONTACT:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 20 7862 6390

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.

Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

 

Dr Michael Koslowski listed in the top 20 translational researchers

CAMBRIDGE, UK – 6 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce that its Chief Medical Officer, Dr Michael Koslowski has been listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology. Based on the number of patents granted, the annual ranking of faculty is published in the bioentrepreneur section of the publication.

Michael Koslowski was granted 10 patents in 2015. His most cited patents titles include monoclonal antibodies for the treatment of cancer and the identification of tumour-associated antigens for diagnosis and therapy.

Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We are very pleased that Michael has been recognised for his stellar work to date, and are delighted that he is part of our team to support our growth strategy as we continue to transition our business into a clinical stage organisation. Michael’s experience and in-depth knowledge of clinical development enables us to further advance our DUB platform. With a wealth of international, commercial and scientific experience, our team continues to create and deliver value from the diverse therapeutic opportunities generated by our discovery platform.”

The full ranking can be found here:

http://www.nature.com/bioent/2016/160901/full/bioe.2016.9.html

For more information:

CONTACT:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 20 7862 6390

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.

Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

 

Mission Therapeutics wins ‘One to Watch’ Private UK Life Science Company of the Year

CAMBRIDGE, UK – 7 September 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce it has won the “One to Watch Private UK Life Science Company of the Year” Award at the Biotech & Money 2016 Awards Dinner.

Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We are very pleased to have been recognized as the “One to Watch Private UK Life Science Company of the Year” Award, voted for by a highly experienced judging panel, as well as participants from the life science community. This has been a transformational year for Mission Therapeutics. Our recent fundraise supported by high profile investors is a strong endorsement of Mission’s unique discovery platform and will enable us to execute the company’s strategy by advancing our pipeline programmes through early clinical development.”

Held in London at the historical Gibson Hall, the inaugural Biotech & Money 2016 Awards Dinner was attended by over 250 C-Suite executives, investors, key stakeholders and KOLs in the sector.

For more information:

CONTACT:

Mission Therapeutics Ltd

Anker Lundemose

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 20 7862 6390

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.

Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

 

Mission Therapeutics to Attend and Present at Conferences in June and July 2016

CAMBRIDGE, UK – 3 June 2016MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:

(1) American Society of Clinical Oncology (ASCO) Annual Meeting, 3–7 June 2016, McCormick Place, Chicago, Illinois, USA

Michael Koslowski, Chief Medical Officer, and Anker Lundemose, Chief Executive Officer, to attend conference

ASCO is one of the key global conferences in the Oncology space, bringing together 35,000 oncology professionals from around the world. The event has both educational and scientific sessions to address new therapies, treatment modalities, research and ongoing controversies in the field. Over 3,000 abstracts are submitted internationally from over 80 countries.

 

(2) Ubiquitin & Autophagy Conference, 4–7 July 2016, Goethe University Hospital, Frankfurt, Germany

The inaugural conference brings together leading experts in the field of quality control in cells, with a focus on ubiquitin and autophagy and will feature over 40 renowned speakers at the event.

 

(3) European Association for Cancer Research Conference (EACR), 9–12 July 2016, Manchester Central Convention Complex, Manchester, UK

The EACR is one of Europe’s largest dedicated conference on basic and translational research. This year’s theme is: ‘From Basic Research to Precision Medicine’ and will feature world class speakers from around the world covering the most innovative research topics in the fields of diagnostic tools and cancer treatment.

 

For further events, please visit the MISSION Therapeutics website. 

 

For more information:

 CONTACT:

 MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 (0) 20 7862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.

Mission Therapeutics to Attend and Present at Conferences in May 2016

CAMBRIDGE, UK – 4 May 2016MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:

(1) Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease conference, 4 – 6 May, Wellcome Genome Campus, Hinxton, Cambridge, UK

Michael Koslowski, Chief Medical Officer, to attend the conference

The conference will bring together world leaders in the field of translational mitochondrial medicine in an interactive program designed to engage and inspire a new generation of mitochondrial researchers, who will harness this new technology to prevent and treat these devastating diseases. The meeting attracts international delegates interested in mitochondrial diseases, working in molecular genetics, biochemistry, pathology, and clinical medicine.

(2) Bio€quity Europe, 10 – 11 May 2016, Scandic Hotel, Copenhagen, Denmark

Anker Lundemose, Chief Executive Officer, to present on Tuesday 10th May at 4.00 pm CET

David Luther, Chief Financial Officer, to attend the conference

Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.

(3) EMBO Conferences Cellular signalling and Cancer therapy, 27 – 31 May 2016, Hotel Croatia Cavtat, Dubrovnik, Croatia

The EMBO Conference brings together leading experts from different scientific disciplines to discuss new findings and future challenges in cancer research. The aim of this edition is to share new insights in our understanding of cancer and discuss how these insights provide new strategies for the development and improvement of diagnostic tools and cancer treatment.

For further events, please visit the MISSION Therapeutics website.

 

For more information, contact:

MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 (0) 20 7862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge

Mission Therapeutics to Present at Conferences in March – April 2016

CAMBRIDGE, UK – 31 March 2016MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, Dr Xavier Jacq, VP Scientific Affairs, Dr Paul Wallace, Chief Business Officer and Dr Michael Koslowski, Chief Medical Officer & EVP Research & Development, are scheduled to attend the following events:

(1) Biotechs and the City Spring, 31 March 2016, London, UK

Dr Anker Lundemose, CEO, to present an overview of MISSION Therapeutics on Thursday, 31 March at 6.00pm GMT

Biotechs and the City events are organised by Biotech and Money and feature highly topical short presentations or a thematical 45 minute Panel Discussion from industry Executives.

(2) Mitochondrial dynamics – Keystone Symposia, 3- 7 April 2016, Colorado, USA

Dr Xavier Jacq, VP Scientific Affairs, to attend

This meeting will highlight the latest advances in diverse disciplines including neurology, aging, cancer research, autophagy, membrane morphogenesis, structural biology and bioenergetics. The programme groups the best senior and junior scientists in these disciplines to break down barriers between different fields of research and promote innovation. As the most important discoveries in mitochondrial dynamics lie ahead, the interactions at this meeting should play a key role in their advance.

(3) BIO – Europe Spring, 4-6 April 2016, Stockholm, Sweden

Dr Paul Wallace, Chief Business Officer, to attend

The premier springtime partnering conference which annually attracts an international “who’s who” from biotech, pharma and finance for three days of high calibre networking.

(4) AACR annual meeting 2016, 16 – 20 April 2016, New Orleans, Louisiana

Dr Xavier Jacq, VP Scientific Affairs, and Dr Michael Koslowski, Chief Medical Officer & EVP Research and Development, to attend

The AACR Annual Meeting will focus on “Delivering Cures Through Cancer Science” reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research.

(5) BioTrinity, 25- 27 April 2016, London, UK

Dr Paul Wallace, Chief Business Officer, to attend

BioTrinity is the nexus of a booming life sciences innovation ecosystem and provides a unique platform for R&D, global pharma and investor companies across the life sciences industry to achieve their business objectives; to secure funding, seek acquisition and in-licensing deals and grow their network.

For further events, please visit the MISSION Therapeutics website.

For more information:

CONTACT:

MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199

Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Email: missiontherapeutics@humebrophy.com
Tel: +44 (0) 20 7862 6390

NOTES TO EDITORS:

About MISSION Therapeutics
MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.

Mission Therapeutics to Present at Conferences in March 2016

 CAMBRIDGE, UK – 1 March 2016MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, and Dr Xavier Jacq, VP Scientific Affairs, are scheduled to present at the following events:

(1) 6th Ubiquitin Research and Drug Discovery GTC Conference, 29 February-1 March, 2016, San Diego, CA

Dr Xavier Jacq, VP Scientific Affairs, to present on Tuesday, 1st March 2016 at 11.25 am PST on “Discovery of highly selective DUB inhibitors with in vivo pre-clinical activity”

This conference provides a forum for researchers from both industry and academia to learn about recent advances in basic science and drugs that target the ubiquitin/proteasome system. Topics will include autophagy in cancer, developments with deubiquitinating enzymes, and novel drug targets in the ubiquitin system.

(2) Cowen and Company 36th Annual Health Care Conference, 7-9 March 2016, The Boston Marriott Copley Place, Boston, Massachusetts

Anker Lundemose, CEO, to present on Tuesday, 8th March 2016 at 3.30 pm EST

Cowen and Company’s conferences belong to major industry events and connects top institutional investors with leading companies in the healthcare sector.

(3) 9th Annual European Life Science CEO Forum & Exhibition, 15-16 March 2016, Hilton Zurich Airport Hotel, Switzerland

Anker Lundemose, CEO, to speak on Tuesday, 15th March 2016 at 2.00 pm CET on the panel “Platform Technologies & Novel Therapeutics Panel” as well as present an overview of MISSION therapeutics at 4.45 pm CET

The event brings together venture-funded and small-cap companies as well as leading investors, pharmas, and scientific thought leaders. The event includes sessions on Public Markets and M&A, Investment, Partnering as well as panels on: Clinical Development, Regulation in Europe, Innovation and BD&L in Oncology as well as Platform Technologies & Novel Therapeutics.

(4) Keystone Symposia on Molecular and Cellular Biology: Ubiquitin Signaling (X3), 13-17 March 2016, Whistler Conference Centre, Whistler, British Columbia, Canada

Dr Xavier Jacq, VP Scientific Affairs, to present on Monday, 14th March 2016 at 5.00 pm PST on “Role of Ubiquitylation in Control of Autophagy, Short Talk: Inhibitors of USP30 as a Potential Treatment of Parkinson’s disease And Other Mitochondrial Dysfunctions”

Organized by Keystone Symposia on Molecular and Cellular Biology, the conference aims to connect the scientific community and accelerate life science discovery. The meeting will focus on how ubiquitylation controls processes such as autophagy, neurodegenerative diseases, hypertension and the immune system.

 

For more information:

 CONTACT:

 MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

 Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 (0) 20 7862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.

MISSION Therapeutics Raises £60 million to Progress Development of Novel DUB Inhibitors from Innovative Drug Platform

Woodford Patient Capital Trust joins existing syndicate supporting transition to clinical development 

CAMBRIDGE, UK – 2 February 2016MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced it has raised £60 million. The financing was jointly led by Imperial Innovations Businesses LLP (“Innovations”) and new investor Woodford Patient Capital Trust Plc (“WPCT”), with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.

The £60 million will enable MISSION to maximize the potential of its world leading DUB platform and advance a series of first-in-class small molecule drugs candidates targeting specific DUBs into clinical development.

Anker Lundemose, Chief Executive Officer, MISSION Therapeutics commented:MISSION Therapeutics has attracted one of the highest profile investor syndicates in Europe. We welcome WPCT and thank our existing investors for their continued support. This is strong endorsement of our unique discovery platform and will enable us to maximize the potential of multiple lead compounds for diverse therapeutic indications. 2016 will see us progress our advanced programs into regulatory preclinical development and deepen our pipeline, from a position of increased financial strength.”

Rob Woodman, Director of Healthcare Ventures, Imperial Innovations added: “We believe MISSION’s world-class DUB platform has the potential to deliver innovative treatments in indications of high unmet need including neurodegenerative diseases and cancer. The investor group are pleased to support the creative management team in realising the full potential of the ground-breaking discovery chemistry as MISSION enters its next, clinically-centred stage of growth.”

DUBs are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

 

CONTACT:

MISSION Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel +44 1223 497199

 

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 207 862 6390

 

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.

The Company has to date received £27 million in venture capital from a blue chip syndicate comprising institutional (Sofinnova Partners, Imperial Innovations) and corporate (SR One, Roche Venture Fund and Pfizer) investors and is based at the Babraham Research Campus, south of Cambridge.

About Woodford Patient Capital Trust

WPCT is the £800 million investment trust launched in April 2015 by Woodford Investment Management LLP (“Woodford”). The trust invests mainly in early-stage and early-growth companies but also has exposure to some blue-chip companies. Woodford is a fast-growing asset management company built on a founding philosophy of transparency and simplicity. Launched in May 2014, the company has more than £14bn assets under management. Further information can be found at https://woodfordfunds.com